F-STAR THERAPEUTICS INC (FSTX) Fundamental Analysis & Valuation

NASDAQ:FSTX • US30315R1077

Current stock price

7.12 USD
0 (0%)
At close:
7.12 USD
0 (0%)
After Hours:

This FSTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. FSTX Profitability Analysis

1.1 Basic Checks

  • FSTX had negative earnings in the past year.
  • FSTX had a negative operating cash flow in the past year.
FSTX Yearly Net Income VS EBIT VS OCF VS FCFFSTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -10M -20M -30M

1.2 Ratios

  • The profitability ratios for FSTX are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FSTX Yearly ROA, ROE, ROICFSTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for FSTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FSTX Yearly Profit, Operating, Gross MarginsFSTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. FSTX Health Analysis

2.1 Basic Checks

  • FSTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • FSTX has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, FSTX has a worse debt to assets ratio.
FSTX Yearly Shares OutstandingFSTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M
FSTX Yearly Total Debt VS Total AssetsFSTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of 0.67, we must say that FSTX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of FSTX (0.67) is better than 61.16% of its industry peers.
  • A Debt/Equity ratio of 0.15 indicates that FSTX is not too dependend on debt financing.
  • FSTX has a Debt to Equity ratio of 0.15. This is in the lower half of the industry: FSTX underperforms 65.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 0.67
ROIC/WACCN/A
WACC8.16%
FSTX Yearly LT Debt VS Equity VS FCFFSTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 3.38 indicates that FSTX has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.38, FSTX is not doing good in the industry: 67.45% of the companies in the same industry are doing better.
  • FSTX has a Quick Ratio of 3.38. This indicates that FSTX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.38, FSTX is doing worse than 66.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.38
Quick Ratio 3.38
FSTX Yearly Current Assets VS Current LiabilitesFSTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. FSTX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 60.57% over the past year.
  • Looking at the last year, FSTX shows a quite strong growth in Revenue. The Revenue has grown by 18.64% in the last year.
  • FSTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 127.15% yearly.
EPS 1Y (TTM)60.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
Revenue 1Y (TTM)18.64%
Revenue growth 3YN/A
Revenue growth 5Y127.15%
Sales Q2Q%49.8%

3.2 Future

  • The Earnings Per Share is expected to grow by 5.63% on average over the next years.
  • The Revenue is expected to grow by 12.21% on average over the next years. This is quite good.
EPS Next Y-39.55%
EPS Next 2Y-23.23%
EPS Next 3Y-11.79%
EPS Next 5Y5.63%
Revenue Next Year-70.62%
Revenue Next 2Y-69.75%
Revenue Next 3Y-37.51%
Revenue Next 5Y12.21%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
FSTX Yearly Revenue VS EstimatesFSTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
FSTX Yearly EPS VS EstimatesFSTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. FSTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FSTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FSTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FSTX Price Earnings VS Forward Price EarningsFSTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FSTX Per share dataFSTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

  • FSTX's earnings are expected to decrease with -11.79% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.23%
EPS Next 3Y-11.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FSTX Dividend Analysis

5.1 Amount

  • No dividends for FSTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

FSTX Fundamentals: All Metrics, Ratios and Statistics

F-STAR THERAPEUTICS INC

NASDAQ:FSTX (3/8/2023, 8:00:00 PM)

After market: 7.12 0 (0%)

7.12

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13
Earnings (Next)05-08
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap156.51M
Revenue(TTM)21.18M
Net Income(TTM)-44.75M
Analysts48.89
Price Target7.14 (0.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.03%
Min EPS beat(2)-47.48%
Max EPS beat(2)-4.58%
EPS beat(4)2
Avg EPS beat(4)120.51%
Min EPS beat(4)-47.48%
Max EPS beat(4)516.97%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1738.24%
Min Revenue beat(2)-100%
Max Revenue beat(2)3576.47%
Revenue beat(4)3
Avg Revenue beat(4)910.2%
Min Revenue beat(4)-100%
Max Revenue beat(4)3576.47%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.39
P/FCF N/A
P/OCF N/A
P/B 2.75
P/tB 5.88
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-3.05
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0.96
BVpS2.59
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.38
Quick Ratio 3.38
Altman-Z 0.67
F-Score2
WACC8.16%
ROIC/WACCN/A
Cap/Depr(3y)80.51%
Cap/Depr(5y)224.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
EPS Next Y-39.55%
EPS Next 2Y-23.23%
EPS Next 3Y-11.79%
EPS Next 5Y5.63%
Revenue 1Y (TTM)18.64%
Revenue growth 3YN/A
Revenue growth 5Y127.15%
Sales Q2Q%49.8%
Revenue Next Year-70.62%
Revenue Next 2Y-69.75%
Revenue Next 3Y-37.51%
Revenue Next 5Y12.21%
EBIT growth 1Y25.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.25%
EBIT Next 3Y-23.59%
EBIT Next 5Y-14.31%
FCF growth 1Y-57.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.9%
OCF growth 3YN/A
OCF growth 5YN/A

F-STAR THERAPEUTICS INC / FSTX Fundamental Analysis FAQ

What is the fundamental rating for FSTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to FSTX.


What is the valuation status of F-STAR THERAPEUTICS INC (FSTX) stock?

ChartMill assigns a valuation rating of 1 / 10 to F-STAR THERAPEUTICS INC (FSTX). This can be considered as Overvalued.


Can you provide the profitability details for F-STAR THERAPEUTICS INC?

F-STAR THERAPEUTICS INC (FSTX) has a profitability rating of 0 / 10.


What is the financial health of F-STAR THERAPEUTICS INC (FSTX) stock?

The financial health rating of F-STAR THERAPEUTICS INC (FSTX) is 4 / 10.